Advanced Endometrial Cancer: Treatment Optimization : Episode 12

Educating Patients With Endometrial Cancer on Treatment-Related Adverse Events

January 6, 2023

By Courtney R. Arn, APRN-CNP
Kimberly Halla, NP

Commentary

Video

The panel explains how to educate patients on the adverse effects they may experience with chemotherapy, their options for management, and the importance of encouraging patients to contact their care team.

EP: 1.Symptoms and Diagnosis of Endometrial Cancer

EP: 2.Initial Consultation of Patients With Advanced Endometrial Cancer

EP: 3.Conversations with Patients With Advanced Endometrial Cancer Before and After Diagnosis

EP: 4.Resources for Patients With Endometrial Cancer

EP: 5.Patient Profile Presentation: A 76-Year-Old Woman With Advanced Endometrial Cancer

EP: 6.Fertility and Other Treatment Considerations for Patients With Advanced Endometrial Cancer

EP: 7.Currently Available Treatment Modalities in Endometrial Cancer

EP: 8.First-Line Treatments for Patients With Advanced Endometrial Cancer Who Are Unfit for Surgery

EP: 9.Common Adverse Events Seen With Chemotherapy for Advanced Endometrial Cancer

EP: 10.Efficacy of Chemotherapy in Patients with Advanced Endometrial Cancer

EP: 11.Treatment Options for Patients with Recurrent Endometrial Cancer

Now Viewing

EP: 12.Educating Patients With Endometrial Cancer on Treatment-Related Adverse Events

EP: 13.Monitoring Patients on Therapy for Recurrent Endometrial Cancer

EP: 14.Adverse Events Seen With Combination Lenvatinib and Pembrolizumab for Recurrent Endometrial Cancer

EP: 15.Proactive Adverse Effect Management for Patients on Therapy for Endometrial Cancer

EP: 16.Discussing Dose Reductions and Interruptions with Patients on Therapy for Endometrial Cancer

EP: 17.Greatest Unmet Needs for Patients with Endometrial Cancer

EP: 18.Advice for New Nurse Practitioners Working With Patients With Endometrial Cancer

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!

Latest Conference Coverage

Intraoral Photobiomodulation Device Safe, Reduces Oral Mucositis in HNC

Fixed-Duration Mosunetuzumab/Polatuzumab Active in R/R MCL

Zidesamtinib Active, Safe in Pretreated ROS1+ Advanced NSCLC

Mosunetuzumab/Polatuzumab Vedotin Triples PFS in LBCL

View More Latest Conference Coverage

Do Not Sell My Information

Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777